Fighting Cancer with a Tiny Molecule Shows Big Promise
- Researchers at the University of Hawaiʻi at Mānoa, led by Stefan Moisyadi, have demonstrated the potential of nanobodies - tiny molecules - to effectively target adn combat colorectal...
- The study, published in eGastroenterology, reveals that nanobodies showed important efficacy in colorectal cancer models where traditional antibody-based immunotherapies have limited success.
- Antibodies have revolutionized immunotherapy,earning a Nobel Prize for their impact.however, their effectiveness varies considerably across different cancer types.
“`html
Nanobodies Show Promise in Combating Colorectal Cancer
Table of Contents
What Happened?
Researchers at the University of Hawaiʻi at Mānoa, led by Stefan Moisyadi, have demonstrated the potential of nanobodies – tiny molecules – to effectively target adn combat colorectal cancer. This research builds on nearly a decade of refinement of the nanobody concept.
The study, published in eGastroenterology, reveals that nanobodies showed important efficacy in colorectal cancer models where traditional antibody-based immunotherapies have limited success.
What are Nanobodies and Why are They Different?
Antibodies have revolutionized immunotherapy,earning a Nobel Prize for their impact.however, their effectiveness varies considerably across different cancer types. Colorectal cancer, in particular, frequently enough proves resistant to antibody treatments.
Nanobodies, derived from the immune system of camelids (like llamas and camels), are significantly smaller than conventional antibodies. This smaller size offers several advantages:
- Enhanced Tissue Penetration: Their small size allows them to penetrate solid tumors more effectively, reaching cancer cells that larger antibodies might miss.
- Improved Stability: Nanobodies are generally more stable than antibodies, making them easier to manufacture and store.
- Reduced Immunogenicity: They are less likely to trigger an immune response in patients, minimizing potential side effects.
Moisyadi explains, “They work in some cancers, but not all. In colorectal cancer, they hardly work at all. but when we used nanobodies, bingo, it worked.”
The Research Findings: A Deeper Dive
The research team at the Yanagimachi Institute for Biogenesis Research and the John A. Burns School of Medicine (JABSOM) focused on targeting specific proteins on the surface of colorectal cancer cells. The nanobodies were engineered to bind to these proteins, triggering an immune response that selectively destroys the cancer cells.
The study utilized both in vitro (laboratory) and in vivo (animal model) experiments. Results showed:
| Experiment Type | Key Findings |
|---|---|
| In Vitro (Cell Cultures) | Nanobodies demonstrated strong binding affinity to target proteins on colorectal cancer cells. |
| In Vivo (Mouse Models) | Nanobody treatment significantly reduced tumor growth and improved survival rates in mice with colorectal cancer. |
| control Group (No Treatment) | Tumors continued to grow, and survival rates remained low. |
Further analysis revealed that the nanobodies activated key immune cells, including T cells, to attack the cancer cells. This suggests that nanobodies can effectively reprogram the immune system to fight cancer.
Who is Affected and What Does This Mean?
This research has significant implications for patients with colorectal cancer, a leading cause of cancer-related deaths worldwide. Current treatment options,